the Study of the Association Between the Gut Microbiota and Central Serous Chorioretinopathy
Second Affiliated Hospital, School of Medicine, Zhejiang University
400 participants
May 27, 2024
INTERVENTIONAL
Conditions
Summary
To investigate the potential association between gut microbiota and central serous chorioretinopathy (CSC), we have observed in our clinical practice that CSC patients often experience chronic gastrointestinal issues. This observation has led us to hypothesize that CSC may be associated with gut dysbiosis. The Bifidobacterium genus is widely recognized as a beneficial gut bacterium, and numerous well-established Bifidobacterium supplements are available on the market. To explore this possible connection, we will collect fecal samples from both CSC patients and healthy individuals. Using whole-metagenome shotgun sequencing, we will compare the gut microbiota compositions of the two groups to determine if significant differences exist. Additionally, we will randomly assign patients to two groups: one group will receive Bifidobacterium supplements for at least one month, while the other group will receive a placebo. We will then assess whether the group receiving the supplements experiences faster recovery and lower relapse rates compared to the placebo group.
Eligibility
Inclusion Criteria4
- Age 18 to 60 years
- Diagnosis of acute central serous chorioretinopathy (CSC) (affected eye: ① FFA and ICGA showing typical CSC manifestations, ② presence of subretinal fluid (SRF) at the macular fovea, ③ disease duration ≤ 6 months)
- Best Corrected Visual Acuity (BCVA): 53 to 86 letters
- Other: No significant systemic diseases, signed informed consent, and able to commit to follow-up
Exclusion Criteria5
- Presence of significant systemic diseases
- BCVA of 20/200 or worse
- Presence of choroidal or retinal atrophy in the macular fovea of the affected eye
- Presence of choroidal neovascularization (CNV), age-related macular degeneration (AMD), polypoidal choroidal vasculopathy (PCV), diabetic retinopathy (DR), choroidal hemangioma, pigment epithelial detachment (PED), etc., in the affected eye
- High myopia in the affected eye
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
the Bifidobacterium genus supplement
Placebo
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06527326